Case Report on Recombinant Coagulation Factor VIIa in the Treatment of Three Haemophilia A Patients with Inhibitors in Singapore

H J Ng,* MBBS, M Med (Int Med), MRCP (UK), L H Lee,** FAMS, MBBS, M Med (Int Med)

Abstract

Introduction: We report the first experiences with use of recombinant coagulation Factor VIIa (rFVIIa) in the treatment of haemophilia A patients with inhibitors in Singapore and discuss observations in 3 patients. Clinical Picture: Case 1 bled on two separate occasions into his neck muscles and vocal cord. Case 2 had gross haematuria from bleeding in the renal calyces. Case 3 bled into the parotid muscles. Treatment: rFVIIa in doses, ranging from 50 ug/kg to 90 ug/kg, at different dosing intervals, were used. Outcome: Excellent responses were seen in doses of 70 and 90 ug/kg. Conclusion: rFVIIa is highly effective, both clinically and cost-wise, in the treatment of these patients.

Key words: Bleeding, Cost-effectiveness, Dosing, Haemophiliacs, Response

* Registrar
** Consultant

Department of Haematology
Singapore General Hospital

Address for Reprints: Dr Ng Heng Joo, Department of Haematology, Singapore General Hospital, Outram Road, Singapore 169608.
E-mail: ghenhj@sgh.com.sg